IP Library Granted Patent US 6,939,342
Granted Patent B2
US 6,939,342 · App. 10/318,443 · Granted Sep 6, 2005

System and method for evaluating a secondary LASIK treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,939,342
App. No.
10/318,443
Granted
Sep 6, 2005
Kind
B2
Abstract

A method and system are disclosed for evaluating the safety of a prospective secondary LASIK treatment to correct a person's vision. The difficulties with making an accurate, direct measurement of corneal thickness of a cornea having a pre-existing keratectomy are overcome by using pre-LASIK topography and pachymetry measurements, and per- and post-LASIK wavefront measurements to determine post-LASIK corneal thickness, and thus the suitability and safety of a prospective secondary LASIK procedure. A system embodiment includes diagnostic and computing platforms for generating and analyzing data, and a device readable medium for storing and transferring an instruction to a laser ablation system.

Claims (23)

1. A method for evaluating the safety of a prospective secondary LASIK procedure, comprising:

a) obtaining a pre-LASIK corneal thickness measurement;

b) obtaining a pre-LASIK wavefront measurement;

c) obtaining a post-LASIK wavefront measurement;

d) determining an amount of corneal material removed by the LASIK procedure from (b) and (c); and

e) determining the post-LASIK corneal thickness from the difference between (a) and (d), thereby determining the safety of the procedure.

2. The method of claim 1 , wherein step (a) comprises obtaining an anterior corneal topography measurement, a posterior corneal topography measurement, and a corneal pachymetry measurement.

3. The method of claim 1 , wherein step (d) comprises determining the optical path difference between the pre- and post-LASIK wavefront measurements and using this information with index of refraction data to determine the removed tissue amount.

4. The method of claim 1 , further comprising

using the post-LASIK wavefront measurement to determine an amount of a prospective secondary corneal tissue removal for a desired vision correction; and

determining whether the post-LASIK corneal thickness is sufficient to support a recommendation for the secondary corneal tissue removal.

5. The method of claim 4 , further comprising indicating one of a positive and a negative recommendation for the further removal of corneal tissue.

6. The method of claim 4 , comprising displaying the recommendation on a graphical user interface.

7. A system for determining the safety of a prospective secondary LASIK treatment, comprising:

a diagnostic platform including a component adapted to measure data indicative of a corneal thickness of a patient's eye, and a component adapted to measure data indicative of a wavefront error of the patient's eye, prior to a LASIK treatment on the eye;

a computing platform operatively connected to the diagnostic platform, capable of receiving and storing the diagnostic data and other data, and determining a primary ablation profile that is indicative of an amount of corneal tissue to be removed by a primary LASIK treatment to effect a desired vision correction based upon the diagnostic and other data, wherein the computing platform will provide an indicia of whether the corneal thickness is sufficient for the primary LASIK treatment based upon a primary corneal thickness measurement;

wherein the computing platform is capable of receiving and storing data indicative of a post-LASIK wavefront error of the patient's eye and determining a secondary ablation profile that is indicative of an amount of corneal tissue to be removed by a prospective secondary LASIK treatment to effect the desired vision correction, further wherein the computing platform is programmed to determine the difference between the primary corneal thickness measurement and the amount of corneal tissue removed by the primary LASIK procedure.

8. The system of claim 7 further comprising a device readable medium operably compatible with the computing platform and adapted to receive an instruction reference relating to at least one of the primary ablation profile and the secondary ablation profile, said medium being further operably compatible with a laser system for effecting said primary or secondary LASIK procedure.

9. The system of claim 7 further comprising a graphical user interface (GUI) operably connected to one of the diagnostic platform and the computing platform.

10. The system of claim 9 , wherein the GUI can display a recommendation for the secondary LASIK treatment.

11. The system of claim 7 , wherein the component adapted to measure data indicative of a corneal thickness of a patient's eye includes at least one of a topography device, an OCT device, and an ultrasonic pachymetry device; and the component adapted to measure data indicative of a wavefront error of the patient's eye includes at least one of an aberrometer, an interferometer, and a refractometer.

12. The system of claim 7 , wherein the other data comprises at least one of index of refraction data, patient data, clinician data, and system data.

13. The system of claim 7 , wherein the diagnostic platform is an integrated device adapted to provide the necessary diagnostic data to the computing platform.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →